Høyeraal H M, Frøland S S, Salvesen C F, Munthe E, Natvig J B, Kåss E, Blichfeldt P, Hegna T M, Revlem E, Sandstad B, Hjort N L
Ann Rheum Dis. 1978 Apr;37(2):175-9. doi: 10.1136/ard.37.2.175.
A previously pilot study of treatment with transfer factor in 3 patients with juvenile rheumatoid arthritis (JRA) gave promising results. However, in this small and open study no definite conclusions could be drawn. Therefore, a double-blind group trial was performed in 12 JRA patients treated with transfer factor, and in 12 placebo-treated control patients. The patients were evaluated clinically, by laboratory tests, and by estimation of different lymphocyte populations and cell-mediated immunity in vitro and in vivo. Transfer factor was not found to be of significant therapeutic value in patients with JRA. The only statistically significant difference between the two groups was a greater reduction in the percentage of T lymphocytes in transfer factor-treated patients than in control patients. The significance of this is difficult to explain and could have appeared by chance. No side effects of treatment with transfer factor were noted.
先前对3例青少年类风湿性关节炎（JRA）患者进行的转移因子治疗初步研究取得了有希望的结果。然而，在这项小型开放性研究中无法得出明确结论。因此，对12例接受转移因子治疗的JRA患者和12例接受安慰剂治疗的对照患者进行了双盲分组试验。通过临床评估、实验室检查以及体外和体内不同淋巴细胞群体及细胞介导免疫的评估对患者进行了评价。未发现转移因子对JRA患者具有显著治疗价值。两组之间唯一具有统计学意义的差异是，接受转移因子治疗的患者中T淋巴细胞百分比的降低幅度大于对照患者。其意义难以解释，可能是偶然出现的。未观察到转移因子治疗的副作用。
